ACTIVE

Perseus Biomics

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

-2,5 M €

-15.8% YoY

Gross margin

320,0 k €

-46.1% YoY

Equity

2,1 M €

-54.5% YoY

Workforce

14,3 ETP

-16.4% YoY

What does Perseus Biomics do?

Perseus Biomics is a Private limited company incorporated in 2016. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Leuven. It employs on average 14,3 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0650.946.412

Incorporation

31/03/2016

Legal form

Private limited company

Registered office

Gaston Geenslaan 3
3001 Leuven · FlandreSee on map

Contributed capital

10 666 421,29 €

Latest accounts

31/12/2025

Average workforce

14,3 ETP

Activities (NACE)

21100Manufacture of basic pharmaceutical products· main 21100Manufacture of basic pharmaceutical products 72101Research and experimental development on natural sciences and engineering 72110Research and experimental development on biotechnology 21201Manufacture of pharmaceutical preparations 21201Manufacture of pharmaceutical preparations+2

Joint committees (2)

Signals

Solid equityHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 9 financial years

	2025		2024		2023		2022		2021		2020		2019		2018		2017
Income statement
Gross margin	320,0 k €	-46.1%	593,7 k €	+24.9%	475,4 k €	+38.1%	344,1 k €	+124%	153,6 k €	+200%	-154,0 k €	-23474%	-653,4 €	-37.9%	-473,7 €	+74.7%	-1,9 k €
EBITDA	-1,0 M €	+0.2%	-1,0 M €	-26.2%	-829,0 k €	-19.0%	-696,9 k €	-144%	-285,1 k €	-12.0%	-254,5 k €	-24025%	-1,1 k €	-8.3%	-974,1 €	+63.3%	-2,7 k €
Operating result	-2,5 M €	-16.0%	-2,2 M €	-37.7%	-1,6 M €	-32.0%	-1,2 M €	-143%	-492,2 k €	-66.2%	-296,0 k €	-27959%	-1,1 k €	-8.3%	-974,1 €	+74.6%	-3,8 k €
Net result	-2,5 M €	-15.8%	-2,1 M €	-4.7%	-2,0 M €	-69.1%	-1,2 M €	-149%	-483,1 k €	-64.1%	-294,4 k €	-26874%	-1,1 k €	-9.0%	-1,0 k €	+74.2%	-3,9 k €
Balance sheet
Equity	2,1 M €	-54.5%	4,5 M €	-2.8%	4,6 M €	+13733%	33,6 k €	-97.3%	1,2 M €	-23.7%	1,6 M €	+705387%	229,4 €	-82.6%	1,3 k €	-43.1%	2,3 k €
Total assets	5,2 M €	-4.0%	5,5 M €	+3.8%	5,3 M €	+22.3%	4,3 M €	+42.8%	3,0 M €	+80.5%	1,7 M €	+727790%	229,4 €	-87.6%	1,8 k €	-20.4%	2,3 k €
Cash	56,6 k €	-81.1%	299,9 k €	-81.2%	1,6 M €	-3.3%	1,6 M €	+59.4%	1,0 M €	-12.1%	1,2 M €	+512412%	229,4 €	-87.6%	1,8 k €	-15.7%	2,2 k €
Debts	3,2 M €	+440%	590,5 k €	+63.8%	360,6 k €	-89.3%	3,4 M €	+89.7%	1,8 M €	+3362%	51,4 k €		–		526,6 €		–
Other
Workforce	14,3 ETP	-16.4%	17,1 ETP	+11.8%	15,3 ETP	+25.4%	12,2 ETP	+122%	5,5 ETP	+206%	1,8 ETP		–		–		–

Estimate

Indicative valuation

As an indication, this company is worth

between 1 M€ and 2,5 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 7 active · 7 ended

Active mandates

Adam Roslewski

Director

Active

Ahmed Diar

Director

Active

Johan Hofkens

Director

Active

Nazir Hanna

Director

Active

Thomas Prischenk

Director

Active

Volker Leen

Director

Active

Walid Hanna

Director

Active

Ended mandates

Odyssey Development & Consulting SARL

Director · since 01 janvier 2025

Represented by Walid Hanna

Ended

Albiez Michael

Director · since 20 mai 2020

Ended

Johan Hofkens

Manager

Ended

Nazir Hanna

Manager

Ended

At this address

Other companies at this address

Company	CBE no.
AstriVax Therapeutics● Active	0787.990.881
AUGUSTINE THERAPEUTICS● Active	0722.705.230
COULTREON BIOPHARMA● Active	1019.429.814
K5 Therapeutics● Active	0757.718.072
Metaptys● Active	0554.664.311
Montis Biosciences● Active	0730.979.429
QUOMAK● Active	0448.488.111
ReWind Therapeutics● Active	0682.626.216
Stichting Administratiekantoor Coultreon● Active	1040.853.946
Tavira Therapeutics● Active	0802.591.262
VEDRA THERAPEUTICS● Active	1039.565.628

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	29/07/2026	07/08/2025	18/07/2024	23/08/2023	15/07/2022	30/08/2021
General meeting	12/06/2026	13/06/2025	12/07/2024	10/06/2023	10/06/2022	11/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

9 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	12/06/2026	29/07/2026	Dutch	PDF
Abridged model	31/12/2024	13/06/2025	07/08/2025	Dutch	PDF
Abridged model	31/12/2023	12/07/2024	18/07/2024	Dutch	PDF
Abridged model	31/12/2022	10/06/2023	23/08/2023	Dutch	PDF
Abridged model	31/12/2021	10/06/2022	15/07/2022	Dutch	PDF
Abridged model	31/12/2020	11/06/2021	30/08/2021	Dutch	PDF
Micro model	31/12/2019	12/06/2020	17/09/2020	Dutch	PDF
Micro model	31/12/2018	14/06/2019	14/08/2019	Dutch	PDF
Micro model	31/12/2017	08/06/2018	09/08/2018	Dutch	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 1 M€ and 2,5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 7 active · 7 ended

Active mandates

Adam Roslewski

Director

Active

Ahmed Diar

Director

Active

Johan Hofkens

Director

Active

Nazir Hanna

Director

Active

Thomas Prischenk

Director

Active

Volker Leen

Director

Active

Walid Hanna

Director

Active

Ended mandates

Odyssey Development & Consulting SARL

Director · since 01 janvier 2025

Represented by Walid Hanna

Ended

Albiez Michael

Director · since 20 mai 2020

Ended

Johan Hofkens

Manager

Ended

Nazir Hanna

Manager

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates15/09/2025
ONTSLAGEN - BENOEMINGEN
PDF
Mandates21/03/2025
MAATSCHAPPELIJKE ZETEL - ONTSLAGEN - BENOEMINGEN
PDF
Capital / shares27/09/2024
KAPITAAL - AANDELEN
PDF
Mandates12/01/2024
ONTSLAGEN - BENOEMINGEN
PDF
Capital / shares19/06/2023
WIJZIGING RECHTSVORM - DIVERSEN - KAPITAAL - AANDELEN
PDF
Mandates09/12/2022
ONTSLAGEN - BENOEMINGEN
PDF
Mandates25/07/2022
ONTSLAGEN - BENOEMINGEN
PDF
Registered office13/10/2021
MAATSCHAPPELIJKE ZETEL
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 2025-2,5 M €↓
2024
Annual accounts 2024-2,1 M €↓
2023
Annual accounts 2023-2,0 M €↓
2022
Annual accounts 2022-1,2 M €↓
2021
Annual accounts 2021-483,1 k €↓
2020
Annual accounts 2020-294,4 k €↓
2019
Annual accounts 2019-1,1 k €↓
2018
Annual accounts 2018-1,0 k €↑
2017
Annual accounts 2017-3,9 k €
31/03/2016
IncorporationPrivate limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

Perseus Biomics

Overview

What does Perseus Biomics do?

Trend over 9 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline